Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.

World journal of gastroenterology - 14 Dec 2017

Kanda Tatsuo, Nirei Kazushige, Matsumoto Naoki, Higuchi Teruhisa, Nakamura Hitomi, Yamagami Hiroaki, Matsuoka Shunichi, Moriyama Mitsuhiko

Abstract excerpt

The recent development of direct-acting antiviral agents (DAAs) against hepatitis C virus (HCV) infection could lead to higher sustained virological response (SVR) rates, with shorter treatment durations and fewer adverse events compared with regimens that include interferon. However, a relatively small proportion of patients cannot achieve SVR in the first treatment, including DAAs with or without peginterferon...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Resistance, Viral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Therapy, Combination

Share to Hepatitis C

Share to Retreatment

Share to Sustained Virologic Response

Share to Treatment Failure

Share to Viral Nonstructural Proteins

Source

Open in PubMed Open full text

Identifiers

PMID: 29290649
DOI: 10.3748/wjg.v23.i46.8120
PMCID: PMC5739919

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Retreatment of patients with treatment failure of direct-acting antivirals: Focus on hepatitis C virus genotype 1b.PMID 29290649Read ↗

Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.Semantic proximity Read ↗

Key points for the management of hepatitis C in the era of pan-genotypic direct-acting antiviral therapySemantic proximity Read ↗

[Clinical significance of drug resistance-associated mutations in treatment of hepatitis C with direct-acting antiviral agents].Semantic proximity Read ↗

Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.Semantic proximity Read ↗

Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and ChallengesSemantic proximity Read ↗

Retrospective multicentre study on the effectiveness of first-line direct-acting antivirals against hepatitis C virus genotype-1.Semantic proximity Read ↗

Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western ChinaSemantic proximity Read ↗

[Renewed 2015 Clinical Practice Guidelines for Management of Hepatitis C by Korean Association for the Study of the Liver; What Has Been Changed? - Treatment of Chronic Hepatitis C Genotype 1].Semantic proximity Read ↗

Mechanisms of Virologic Failure with Direct-Acting Antivirals in Hepatitis C and Strategies for Retreatment.Semantic proximity Read ↗

Prevalence of HCV resistance-associated substitutions among treatment-failure patients receiving direct-acting antiviral agents.Semantic proximity Read ↗

Incidence and predictors of direct-acting antiviral treatment failure in Turkish patients with chronic hepatitis C genotype 1b infection.Semantic proximity Read ↗

Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.